Xarelto Fatalities Update 2015
•
5 likes•1,540 views
XARELTO (RIVAROXABAN) has been linked to fatalities and serious side effects here is why there are a growing number of lawsuits nationwide https://www.linkedin.com/pulse/20140827205752-21826356-xarelto-fatalities-deaths-side-effects-and-growing-market-share-as-lawsuits-mount
Recommended
Recommended
More Related Content
What's hot
What's hot (20)
Similar to Xarelto Fatalities Update 2015
Similar to Xarelto Fatalities Update 2015 (20)
Recently uploaded
Recently uploaded (20)
Xarelto Fatalities Update 2015
- 1. XARELTO (rivaroxaban) Update on XARELTO Mass Tort Litigation June 23, 2015
- 7. Why Anticoagulants? • Blood Thinners make the blood “thinner” and inhibit clotting • Blood clots can block blood vessels leading to strokes or heart attacks • Blood clots can travel to lungs (emboli) or legs (deep vein thrombosis) • Clotting occurs through a complicated process • Post-Surgery blood clots can lead to complications including Deep Vein Thrombosis (DVT) Pulmonary Emboli (PE) from reduced activity during recuperation
- 9. Natural Clotting • Natural clotting is necessary to stop bleeding but a medical pre-disposition to clotting can present a health problem or lead to medical complications • Post-Operative blood clots can prove fatal and why they get you up and moving as soon as possible after surgery • Added Risk Factors of Age, Obesity, Heart Disease set the table for a Perfect Storm or Medical Cascade of Problems
- 11. Atrial Fibrillation • Irregular heart beat where heart’s upper chambers (Atria) are out of sync with lower chambers (Ventricles) • Undetected or Untreated it can lead to blood clots and complications from blood clots traveling to other organs or parts of the body
- 12. • Age increases risk • Heart Disease • High Blood Pressure • Family History • Obesity • Alcohol Use - Binge Drinking • Chronic Conditions Risk Factors for AFib
- 13. • Diagnosis may involve several tests • Electrocariodgram (ECG) • Portable ECG or Holter Monitor over period of time • Echocardiogram • Blood Tests AFib Diagnosis
- 14. • Damage to the Heart • Heart Attacks • Coronary Artery Disease • Abnormal HeartValves • High Blood Pressure • Congenital Heart Defecs • Metabolic Imbalance • Viral Infections • Lung Disease • Prior Heart Surgery • Sleep Apnea • Stress Illness, Surgery or Pneumonia Potential Causes
- 15. • WARFARIN/COUMADIN (also known as Jantoven, Marevan and Uniwarfin) used as anticoagulant since the 1950’s • Originally introduced in late 1940’s as rat poison or pesticide • Remains a widely prescribed and popular anticoagulant • Onset of anticoagulant qualities is not immediate • Known to Interact with other common medications • Requires dietary restrictions because it interacts with leafy foods or greens with large amounts ofVitamin K • Requires regular or routine blood test monitoring to maintain therapeutic range of dose • INR (International Normalized Ratio) Too High = Risk of Bleeding Too Low = Risk of Blood Clot • Therapeutic Range - Balancing Act • Risk of Hemorrhage/Bleeding Exists Historical Backstory
- 16. Emergent Solution - Antidote • Reversal Agent is known • There is a Known and Time Proven Antidote • Fresh Frozen Plasma • Vitamin K with Prothrombin Complex Concentrate • Vitamin K Intravenously
- 17. New Oral Anticoagulants - NOACs Marketing Message & Appeal For the Masses
- 18. New & Improved - One Dose Fits All
- 19. • PRADAXA (dabigatran etexilate) • Boehringer Ingelheim Pharmaceuticals, Inc. - Ridgefield, CT • XARELTO (rivaroxaban) • Janssen Pharmaceuticals, Inc. - Titusville, NJ • Bayer Healthcare AG - Leverkusen, Germany • ELIQUIS (apixaban) • Briston-Myers Squibb Company - Princeton, NJ • COUMADIN - Registered Trademark Holder • Pfizer Inc. - NewYork, NY Novel Anticoagulants Fueled By Race to Market
- 20. PRADAXA 1st Novel Anticoagulant inYears • Parallel Marketing Themes • No Monitoring • No Dietary Restrictions • Lifestyle Message like birth control
- 21. XARELTO - Market Share Heir Apparent • Parallel Marketing Themes • No Monitoring • No Dietary Restrictions • Lifestyle
- 22. Safety Signals & Red Flags • International Safety Signals - PRADAXA • PRADAXA Litigation • $650M Settlement • BMJ Investigative Report on PRADAXA based on litigation records and information • XARELTO • July 1, 2011 - New Oral Anticoagulant (NOAC) DVT & PE post-op knee/hip • November 4, 2011 - Non-valvular AFib • FDA’s MedWatch • U.S. Food & Drug Administration’s Adverse Event Reporting System (FAERS) • Voluntary Reporting • Companies Required to investigate those they learn about • Cornerstone/Foundation • Gaps in System
- 23. January/February 2013 - WebMd Magazine
- 24. June 6, 2013 - Untitled FDA Letter
- 30. August 2014
- 31. Broad Base of Indications
- 34. Prescribing Information - Major Changes
- 35. XARELTO MDL NO. 2592 IN RE: XARELTO (RIVAROXABAN) PRODUCTS LIABILITY LITIGATION • JPML Transfer Order 12/12/14 • United States District Court Eastern District of Lousiana • MDL No. 2592 • The Honorable Eldon E. Fallon • Experienced, well versed in MDL with ability and willingness to manage case • VIOXX; Chinese DryWall • Magistrate Judge North • Approximately 550+ cases with more anticipated
- 36. http://www.laed.uscourts.gov/Xarelto/Orders/Orders.htm • Pre-Trial Orders • Direct Filing • Joint Complaints • Plaintiff Fact Sheet • Defendant Fact Sheet • Science Day - June 2015 • Common Benefit Order - Pre- Trial Order No. 8
- 37. Defendants
- 38. Multi-Count Complaint • Count I - Strict Liability • Count II - Manufacturing Defect • Count III - Design Defect • Count IV - Failure To Warn • CountV - Negligence • CountVI - Breach of Express Warranty • CountVII - Breach of Implied Warranty • CountVIII - Negligent Misrepresentation • Count IX - Fraud • Count X -Violation of Consumer Protection Laws/Consumer Fraud Laws • Count XI - Loss of Consortium • Count XII - Wrongful Death • Count XIII - Survival Action • Count XIV - State Specific (ie. FL Total Permanent Impairment of Parent) • Jury Trial Demand
- 39. • Serious bleeding events and some XARELTO Fatalities • 2,081 SAE MedWatch Reports with FDA in 2012 • Likely underreported as system if voluntary not compulsory and notorious for blind spots • At least 151 Deaths • $2B in Sales in 2013 • RECORD Studies design flaw and in manner conducted • “Systematic discarding of medical records” and thus unreliable P54 • ROCKET AF study compared to warfarin. Poorly managed group and made it look “non-inferior” • Cases Filed in MDL growing over 500+ • Science Day was last week • Document review underway
- 43. XARELTO - Philadelphia, PA
- 45. CNN - Ad 2015
- 46. 2015
- 47. May 2015 - Paid Search
- 51. Case Acquisition • Traditional sources: • TV, Print, Radio & Web • Referrals • Co-counsel • Neighbors (Literally) • Friends & Family • Demographic & Illness Driven • Screen carefully • Proof of Use • Latency/Onset • Other Medications in Use • Adverse Event or Side Effects being litigated • Bleeding Events • XARELTO Fatalities • Gastrointestinal Bleeding
- 57. July 27, 2015 - Risperdal Webinar